The Vermont lawmaker’s well-chronicled antagonism toward lobbyists has some concerned they’ll be unable to blunt criticism of their clients and struggle to gain traction on changes to a drug discount program involving pharmaceutical companies and hospitals or to revisit association health plans after a Trump-era rule around them was voided.

Multiple lobbyists representing health insurers, pharmaceutical companies, providers and health systems told POLITICO they’re planning to “bank shot” their advocacy to get their messages across — lobbying other lawmakers on the committee and getting into the ears of progressive policymakers and left-leaning organizations.

A shifting agenda: Leading the panel gives Sanders, a longtime proponent of “Medicare for All,” oversight authority over some of his policy priorities.

Sanders has talked about working to boost access to primary care, expand early childhood education and the health care workforce and raise minimum wages. He could potentially take on new issues such as climate change’s health impacts and others that don’t sit in the political center, like his Medicare for All.

Sanders has said he plans to work across the aisle while seeking to advance his agenda. He’s already met with Sen. Susan Collins (R-Maine) on rural health policy, who says he’ll have more success if he focuses on that than Medicare for All.

Many in Washington, D.C., will be closely watching his collaboration with the committee’s incoming ranking member, Sen. Bill Cassidy (R-La.), who also wants to make addressing the nursing shortage a priority.